

## **Provider Bulletin**

May 2023

# Quarterly pharmacy formulary change notice

This communication applies to the Medicaid programs for Simply Healthcare Plans, Inc. (Simply) and Clear Health Alliance (CHA).

The formulary changes listed in the table below were reviewed and approved at the Agency for Healthcare Administration's March 2023 Pharmacy and Therapeutics Committee meeting.

Effective April 1, 2023, the changes outlined below apply to all members enrolled with Simply and CHA. Please remember to read the footnotes at the end of the table.

| Effective for all Statewide Medicaid Managed Care Managed Medical Assistance members on April 1, 2023 |                                        |                |  |
|-------------------------------------------------------------------------------------------------------|----------------------------------------|----------------|--|
| Therapeutic class                                                                                     | Drug                                   | Revised status |  |
| ACNE AGENTS, TOPICAL                                                                                  | CLINDAMYCIN PHOSPHATE GEL<br>(TOPICAL) | PDL            |  |
| ANDROGENIC AGENTS,<br>ORAL                                                                            | TLANDO (ORAL)                          | Non-PDL        |  |
| ANGIOTENSIN<br>MODULATORS                                                                             | BENAZEPRIL HCTZ (ORAL)                 | PDL            |  |
| ANGIOTENSIN<br>MODULATORS                                                                             | QUINAPRIL HCTZ (ORAL)                  | PDL            |  |
| ANGIOTENSIN<br>MODULATORS                                                                             | TELMISARTAN (ORAL)                     | PDL            |  |
| ANGIOTENSIN<br>MODULATORS                                                                             | TELMISARTAN HCTZ (ORAL)                | PDL            |  |
| ANTICHOLINERGICS / ANTISPASMODICS                                                                     | DARTISLA (ORAL)                        | Non-PDL        |  |
| ANTICHOLINERGICS / ANTISPASMODICS                                                                     | GLYCOPYRROLATE SOLUTION (ORAL)         | PDL            |  |
| ANTICHOLINERGICS / ANTISPASMODICS                                                                     | HYOSCYAMINE SULFATE DROPS (ORAL)       | Non-PDL        |  |
| ANTICONVULSANTS                                                                                       | ZONISADE (ORAL)                        | Non-PDL        |  |
| ANTIDEPRESSANTS, OTHER                                                                                | AUVELITY (ORAL)                        | Non-PDL        |  |
| ANTIDIURETIC HORMONE<br>REPLACEMENT, ORAL &<br>NASAL                                                  | VASOSTRICT (INTRAVENOUS)               | Non-PDL        |  |
| ANTIMIGRAINE AGENTS, OTHER                                                                            | AJOVY (SUBCUTANEOUS)                   | PDL            |  |

| ANTIMIGRAINE AGENTS,                      | AJOVY AUTOINJECTOR                  | PDL     |
|-------------------------------------------|-------------------------------------|---------|
| OTHER                                     | (SUBCUTANEOUS)                      | 100     |
| ANTIMIGRAINE AGENTS,                      | AJOVY AUTOINJECTOR 3-PK             | PDL     |
| OTHER                                     | (SUBCUTANEOUS)                      |         |
| ANTIMYCOBACTERIUM AGENTS                  | MYCOBUTIN (ORAL)                    | PDL     |
| ANTIMYCOBACTERIUM AGENTS                  | RIFABUTIN CAPSULE (ORAL)            | Non-PDL |
| ANTIPSORIATICS, TOPICAL                   | VTAMA (TOPICAL)                     | Non-PDL |
| ANTIPSORIATICS, TOPICAL                   | ZORYVE (TOPICAL)                    | Non-PDL |
| BPH TREATMENTS                            | ENTADFI (ORAL)                      | Non-PDL |
| COLONY STIMULATING FACTORS                | FYLNETRA (SUBCUTANEOUS)             | Non-PDL |
| COLONY STIMULATING FACTORS                | ROLVEDON SYRINGE<br>(SUBCUTANEOUS)  | Non-PDL |
| COLONY STIMULATING FACTORS                | STIMUFEND SYRINGE (SUBCUTANEOUS)    | Non-PDL |
| CYTOKINE AND CAM ANTAGONISTS              | SPEVIGO (INTRAVENOUS)               | Non-PDL |
| GLUCAGON AGENTS                           | DIAZOXIDE SUSPENSION (ORAL)         | Non-PDL |
| GLUCAGON AGENTS                           | PROGLYCEM SUSPENSION<br>(ORAL)      | PDL     |
| GLUCOCORTICOIDS,<br>INHALED               | ALVESCO (INHALATION)                | Non-PDL |
| GLUCOCORTICOIDS,<br>INHALED               | FLOVENT DISKUS (INHALATION)         | PDL     |
| H. PYLORI TREATMENT                       | TALICIA (ORAL)                      | Non-PDL |
| HYPOGLYCEMICS, INSULIN                    | BASAGLAR TEMPO PEN                  | Non-PDL |
| AND RELATED AGENTS                        | (SUBCUTANEOUS)                      |         |
| HYPOGLYCEMICS, INSULIN                    | HUMALOG TEMPO PEN                   | Non-PDL |
| AND RELATED AGENTS                        | (SUBCUTANEOUS)                      |         |
| HYPOGLYCEMICS, INSULIN AND RELATED AGENTS | LYUMJEV TEMPO PEN<br>(SUBCUTANEOUS) | Non-PDL |
| IDIOPATHIC PULMONARY FIBROSIS             | PIRFENIDONE (ORAL)                  | PDL     |
| IMMUNOMODULATORS,                         | TEZSPIRE SYRINGE                    |         |
| ASTHMA                                    | (SUBCUTANEOUS)                      | Non-PDL |
| IMMUNOMODULATORS, ATOPIC DERMATITIS       | TACROLIMUS (AG) (TOPICAL)           | PDL     |
| IMMUNOMODULATORS, ATOPIC DERMATITIS       | TACROLIMUS (TOPICAL)                | PDL     |
| IMMUNOMODULATORS,<br>TOPICAL              | HYFTOR (TOPICAL)                    | Non-PDL |
|                                           |                                     | i e     |

| INTRANASAL RHINITIS AGENTS    | RYALTRIS (NASAL)                             | Non-PDL |
|-------------------------------|----------------------------------------------|---------|
| KERATOLYTICS                  | SALICYLIC ACID GEL (TOPICAL)                 | PDL     |
| METHOTREXATE                  | METHOTREXATE PF VIAL (AG)<br>(INJECTION)     | PDL     |
| MULTIVITAMINS                 | DERMACINRX MULTITAM<br>(ORAL)                | Non-PDL |
| PHOSPHATE BINDERS             | CALCIUM ACETATE CAPSULE<br>(ORAL)            | Non-PDL |
| PHOSPHATE BINDERS             | CALCIUM ACETATE TABLET OTC<br>(ORAL)         | PDL     |
| PHOSPHATE BINDERS             | RENVELA TABLET (ORAL)                        | PDL     |
| PHOSPHATE BINDERS             | SEVELAMER CARBONATE<br>TABLET (AG) (ORAL)    | Non-PDL |
| PHOSPHATE BINDERS             | SEVELAMER CARBONATE<br>TABLET (ORAL)         | Non-PDL |
| SKELETAL MUSCLE               | BACLOFEN SOLUTION (AG)                       | PDL     |
| RELAXANTS                     | (ORAL)                                       | Auto PA |
| SKELETAL MUSCLE<br>RELAXANTS  | NORGESIC (ORAL)                              | Non-PDL |
| STIMULANTS AND RELATED AGENTS | METHYLPHENIDATE ER<br>(RELEXXII) (AG) (ORAL) | Non-PDL |
| STIMULANTS AND RELATED AGENTS | RELEXXII (ORAL)                              | Non-PDL |
| STIMULANTS AND RELATED AGENTS | XELSTRYM (TRANSDERMAL)                       | Non-PDL |
| VASODILATORS, CORONARY        | ISOSORBIDE<br>DINTRATE/HYDRALAZINE (ORAL)    | Non-PDL |

NA = Not applicable (for new products)

#### What action do I need to take?

Please review these changes and work with your Simply and CHA patients to transition them to formulary alternatives. If you determine preferred formulary alternatives are not clinically appropriate for specific patients, you will need to obtain prior authorization (PA) to continue coverage beyond the applicable effective date.

#### What if I need assistance?

We recognize the unique aspects of patients' cases. If for medical reasons your Simply and CHA patient cannot be converted to a formulary alternative, call our Pharmacy department at **877-577-9044** and follow the voice prompts for pharmacy PA.

You can find the *Preferred Drug List* on our provider website at <a href="https://ahca.myflorida.com/medicaid/prescribed\_drug/pharm\_thera/fmpdl.shtml">https://ahca.myflorida.com/medicaid/prescribed\_drug/pharm\_thera/fmpdl.shtml</a>.

If you need assistance with any other item, contact your local Provider Relations representative or call Provider Services at **844-405-4296**.

Simply Healthcare Plans, Inc. Clear Health Alliance Quarterly pharmacy formulary change notice Page 4 of 4

Email is the quickest and most direct way to receive important information from Simply Healthcare Plans, Inc. (Simply) and Clear Health Alliance (CHA).

To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form (Simply: https://bit.ly/3Cm6b8s, CHA: https://bit.ly/2ZoU8so).

### Simply:



#### CHA:

